Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ruanjiantongmai is a Traditional Chinese Medicine (TCM) herbal formulation, typically prepared as a granule, developed by the Shanghai TCM-Integrated Hospital. It is primarily investigated for the treatment of diabetic limb arterial occlusion (DLAO) and atherosclerosis in patients with type 2 diabetes mellitus. The therapeutic rationale of the formula is based on TCM principles of softening hardness and unblocking the vessels to address the inflammatory processes and vascular damage associated with diabetic complications. Clinical research, including trials registered under ChiCTR2000032782, focuses on the drug's ability to modulate inflammatory mechanisms involved in the pathogenesis and development of atherosclerosis in the lower extremities of diabetic patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ruanjiantongmai.